Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: A case series.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 26 citations in OpenAlex.

1. Updated Treatment of Non-Steroidal Anti-Inflammatory Drug-Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report.Allergy · 2026
   Review
2. New insights into the mechanisms of aspirin-exacerbated respiratory disease.Current opinion in allergy and clinical immunology · 2025
   Review
3. Efficacy of Biologics in NSAID-ERD: United Airways From the Nose to the Bronchi.The journal of allergy and clinical immunology. In practice · 2024
   Review
4. [Does aspirin therapy after desensitization still have a role in treatment of chronic rhinosinusitis with nasal polyposis in the era of biologics?]HNO · 2024
   Review
5. Should Biologics Be Used Before Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease?The journal of allergy and clinical immunology. In practice · 2024
   Review
6. Updates on immune mechanisms in aspirin-exacerbated respiratory disease.The Journal of allergy and clinical immunology · 2023
   Review
7. Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?Frontiers in allergy · 2023
   Review
8. Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.The Journal of allergy and clinical immunology · 2021
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as